Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Khatija Ahmed

Datos Biográficos

ID7560386
NOMBREKhatija Ahmed
NOMBRESKhatija
APELLIDOAhmed
FIRMAAHMED K
AFILIACIONESSetshaba Research Centre
ORCID0000-0003-0309-1641
VERIFICADOSí
TOTAL DE OBRAS14
TOTAL DE CITAS0
TOTAL COMO AUTOR14
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2010
AÑO MÁS RECIENTE DE PUBLICACIÓN2026
ÍNDICE H0
  • Pre-exposure Prophylaxis Outcomes from a Multilevel Cluster-Randomized Trial Among Adolescent Girls and Young Women in Tshwane, South Africa

    Open Access•Courtney Peasant Bonner, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2026

  • Strategies to Close the PrEP Uptake Gap Among Transgender People and Men Who Have Sex with Men in Tshwane, South Africa

    Open Access•India Perez-Urbano, Athmanundh Dilraj et al.•ARTICLE•AIDS and Behavior•2024

    HIV Pre-exposure Prophylaxis (PrEP) uptake among transgender (TG) people and gay men and other men who have sex with men (MSM) remains low, despite South Africa being the first African country to approve PrEP. This mixed-methods study used a two-phase explanatory sequential design: (1) quantitative analysis of cross-sectional surveys followed by (2) qualitative in-depth interviews. This study explored facilitators and barriers to PrEP uptake to i…

  • The Importance of the Individual in PrEP Uptake

    Open Access•Courtney Peasant Bonner, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2023

  • ART initiation among women newly diagnosed with HIV in a contraceptive trial in sub-Saharan Africa

    Open Access•Ivana Beesham, Rodal Issema et al.•ARTICLE•AIDS Care•2022

    Current guidelines recommend starting antiretroviral therapy (ART) as soon as possible after HIV diagnosis to reduce morbidity, mortality and onward HIV transmission. We examined factors influencing ART initiation by women who seroconverted during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. ECHO, conducted between 2015 and 2018, enrolled HIV-negative, sexually active women, aged 16-35 years, from four African countries. …

  • Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women

    Open Access•Laura Nyblade, Jacqueline Ndirangu et al.•ARTICLE•BMC Public Health•2022

    Evidence is needed to inform strategies for addressing clinic stigma toward AGYW, with the goal of removing barriers to PrEP services for this group. While awareness has increased and progress has been achieved around the provision of comprehensive, youth-friendly sexual and reproductive health services, these programs need to be adapted for the specific concerns of young people seeking PrEP services. Our findings point to the four key areas note…

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2

    Open Access•Merryn Voysey, Sue Ann Costa Clemens et al.•ARTICLE•The Lancet•2021

    Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Afri…

  • The PrEpare Pretoria Project

    Open Access•W M Wechsberg, F A Browne et al.•ARTICLE•BMC Public Health•2020

    Background Despite increased prevention efforts, HIV remains the leading cause of death among adolescent girls and young women in South Africa. Although research indicates important determinants of HIV acquisition at the individual and interpersonal levels, structural-level stigma and discrimination continue to be critical barriers to reaching and retaining this key population for HIV prevention and sexual and reproductive health services. Innova…

  • Young Women’s Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa

    Open Access•the TRIO Study Team, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2018

    End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy. The TRIO Study, conducted in Kenya and South Africa, enrolled 277 HIV-negative women aged 18-30 in a randomized cross-over study to use each placebo MPT (daily oral tablets, monthly injections, and monthly vaginal ring) for one month. At the end of each month, participants rated how much they liked using the produc…

  • End-Users’ Product Preference Across Three Multipurpose Prevention Technology Delivery Forms

    Open Access•Rachel Weinrib, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2017

    A multipurpose prevention technology (MPT) that combines HIV and pregnancy prevention is a promising women's health intervention, particularly for young women. However, little is known about the drivers of acceptability and product choice for MPTs in this population. This paper explores approval ratings and stated choice across three different MPT delivery forms among potential end-users. The Trio Study was a mixed-methods study in women ages 18-…

  • When and why women might suspend PrEP use according to perceived seasons of risk

    Emily Namey, Kawango Agot et al.•ARTICLE•Culture Health & Sexuality•2016

    Oral pre-exposure prophylaxis (PrEP) using the antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) has been shown to dramatically reduce the risk of HIV acquisition for women at higher risk of infection if taken daily. Understanding when and why women would intentionally stop using an efficacious oral PrEP drug within the context of their 'normal' daily lives is essential for delivering effective PrEP risk-reduction counsell…

  • Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use

    Open Access•Barbara Friedland, Marie C D Stoner et al.•ARTICLE•AIDS and Behavior•2015

    A randomized, placebo-controlled, efficacy trial of Carraguard was unable to demonstrate a reduction in women's risk of HIV infection, which may have been due, in part, to low adherence (gel used in 42 % of vaginal sex acts, on average). A secondary analysis was undertaken to understand baseline factors associated with high adherence (gel used in ≥85 % of sex acts). Women who reported ≥1 vaginal sex act, returned ≥1 opened applicator, and had ≥1 …

  • To tell or not to tell

    Christine A Kelly, Barbara Friedland et al.•ARTICLE•Culture Health & Sexuality•2015

    Gender norms that privilege men's sexual power and pleasure, and distrust of condom use in intimate relationships, leave women vulnerable to HIV and other sexually transmitted infections. Vaginal microbicides allow women to exert a degree of control over their sexual health, through responsibility for product insertion as well as the possibility of covert use. In practice, however, the uptake of new HIV-prevention products is heavily influenced b…

  • Preexposure Prophylaxis for HIV Infection among African Women

    Lut Van Damme, Amy Corneli et al.•ARTICLE•New England Journal of Medicine•2012

    BACKGROUND: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. METHODS: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily. The primary…

  • Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa

    Open Access•Barbara S Mensch, Paul Hewett et al.•ARTICLE•AIDS and Behavior•2010

Sin obras prominentes en esta página.

  • Assessing the Reporting of Adherence and Sexual Activity in a Simulated Microbicide Trial in South Africa

    Open Access•Barbara S Mensch, Paul Hewett et al.•ARTICLE•AIDS and Behavior•2010

  • Preexposure Prophylaxis for HIV Infection among African Women

    Lut Van Damme, Amy Corneli et al.•ARTICLE•New England Journal of Medicine•2012

    BACKGROUND: Preexposure prophylaxis with antiretroviral drugs has been effective in the prevention of human immunodeficiency virus (HIV) infection in some trials but not in others. METHODS: In this randomized, double-blind, placebo-controlled trial, we assigned 2120 HIV-negative women in Kenya, South Africa, and Tanzania to receive either a combination of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) or placebo once daily. The primary…

  • Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use

    Open Access•Barbara Friedland, Marie C D Stoner et al.•ARTICLE•AIDS and Behavior•2015

    A randomized, placebo-controlled, efficacy trial of Carraguard was unable to demonstrate a reduction in women's risk of HIV infection, which may have been due, in part, to low adherence (gel used in 42 % of vaginal sex acts, on average). A secondary analysis was undertaken to understand baseline factors associated with high adherence (gel used in ≥85 % of sex acts). Women who reported ≥1 vaginal sex act, returned ≥1 opened applicator, and had ≥1 …

  • To tell or not to tell

    Christine A Kelly, Barbara Friedland et al.•ARTICLE•Culture Health & Sexuality•2015

    Gender norms that privilege men's sexual power and pleasure, and distrust of condom use in intimate relationships, leave women vulnerable to HIV and other sexually transmitted infections. Vaginal microbicides allow women to exert a degree of control over their sexual health, through responsibility for product insertion as well as the possibility of covert use. In practice, however, the uptake of new HIV-prevention products is heavily influenced b…

  • When and why women might suspend PrEP use according to perceived seasons of risk

    Emily Namey, Kawango Agot et al.•ARTICLE•Culture Health & Sexuality•2016

    Oral pre-exposure prophylaxis (PrEP) using the antiretroviral drug emtricitabine/tenofovir disoproxil fumarate (Truvada) has been shown to dramatically reduce the risk of HIV acquisition for women at higher risk of infection if taken daily. Understanding when and why women would intentionally stop using an efficacious oral PrEP drug within the context of their 'normal' daily lives is essential for delivering effective PrEP risk-reduction counsell…

  • End-Users’ Product Preference Across Three Multipurpose Prevention Technology Delivery Forms

    Open Access•Rachel Weinrib, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2017

    A multipurpose prevention technology (MPT) that combines HIV and pregnancy prevention is a promising women's health intervention, particularly for young women. However, little is known about the drivers of acceptability and product choice for MPTs in this population. This paper explores approval ratings and stated choice across three different MPT delivery forms among potential end-users. The Trio Study was a mixed-methods study in women ages 18-…

  • Young Women’s Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa

    Open Access•the TRIO Study Team, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2018

    End-user input is critical to inform development of multipurpose prevention technology (MPT) products that prevent HIV and pregnancy. The TRIO Study, conducted in Kenya and South Africa, enrolled 277 HIV-negative women aged 18-30 in a randomized cross-over study to use each placebo MPT (daily oral tablets, monthly injections, and monthly vaginal ring) for one month. At the end of each month, participants rated how much they liked using the produc…

  • The PrEpare Pretoria Project

    Open Access•W M Wechsberg, F A Browne et al.•ARTICLE•BMC Public Health•2020

    Background Despite increased prevention efforts, HIV remains the leading cause of death among adolescent girls and young women in South Africa. Although research indicates important determinants of HIV acquisition at the individual and interpersonal levels, structural-level stigma and discrimination continue to be critical barriers to reaching and retaining this key population for HIV prevention and sexual and reproductive health services. Innova…

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2

    Open Access•Merryn Voysey, Sue Ann Costa Clemens et al.•ARTICLE•The Lancet•2021

    Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Afri…

  • ART initiation among women newly diagnosed with HIV in a contraceptive trial in sub-Saharan Africa

    Open Access•Ivana Beesham, Rodal Issema et al.•ARTICLE•AIDS Care•2022

    Current guidelines recommend starting antiretroviral therapy (ART) as soon as possible after HIV diagnosis to reduce morbidity, mortality and onward HIV transmission. We examined factors influencing ART initiation by women who seroconverted during the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. ECHO, conducted between 2015 and 2018, enrolled HIV-negative, sexually active women, aged 16-35 years, from four African countries. …

  • Stigma in the health clinic and implications for PrEP access and use by adolescent girls and young women

    Open Access•Laura Nyblade, Jacqueline Ndirangu et al.•ARTICLE•BMC Public Health•2022

    Evidence is needed to inform strategies for addressing clinic stigma toward AGYW, with the goal of removing barriers to PrEP services for this group. While awareness has increased and progress has been achieved around the provision of comprehensive, youth-friendly sexual and reproductive health services, these programs need to be adapted for the specific concerns of young people seeking PrEP services. Our findings point to the four key areas note…

  • The Importance of the Individual in PrEP Uptake

    Open Access•Courtney Peasant Bonner, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2023

  • Strategies to Close the PrEP Uptake Gap Among Transgender People and Men Who Have Sex with Men in Tshwane, South Africa

    Open Access•India Perez-Urbano, Athmanundh Dilraj et al.•ARTICLE•AIDS and Behavior•2024

    HIV Pre-exposure Prophylaxis (PrEP) uptake among transgender (TG) people and gay men and other men who have sex with men (MSM) remains low, despite South Africa being the first African country to approve PrEP. This mixed-methods study used a two-phase explanatory sequential design: (1) quantitative analysis of cross-sectional surveys followed by (2) qualitative in-depth interviews. This study explored facilitators and barriers to PrEP uptake to i…

  • Pre-exposure Prophylaxis Outcomes from a Multilevel Cluster-Randomized Trial Among Adolescent Girls and Young Women in Tshwane, South Africa

    Open Access•Courtney Peasant Bonner, Alexandra M Minnis et al.•ARTICLE•AIDS and Behavior•2026

Medicine (13 obras) · HIV/AIDS Research and Interventions (12 obras) · Family medicine (10 obras) · Adolescent Sexual and Reproductive Health (9 obras) · Human immunodeficiency virus (HIV (8 obras) · Psychology (8 obras) · HIV, Drug Use, Sexual Risk (7 obras) · Public health (7 obras) · Health psychology (6 obras) · Nursing (6 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae